Hartmann Christian, Mueller Wolf, von Deimling Andreas
Department of Neuropathology, Charité Hospital, Berlin, Germany.
J Mol Med (Berl). 2004 Oct;82(10):638-55. doi: 10.1007/s00109-004-0565-9.
Oligodendroglial gliomas are second only to astrocytic gliomas in frequency. The lack of stringent diagnostic criteria cause high interobserver variation in regard to classification and grading of these tumors. Previous studies have described oligodendrogliomas with features that overlap with those of neurocytic tumors, thus further complicating diagnostic decisions. The increasing need for standardized diagnostic criteria in this subset of gliomas is emphasized by the benefit of adjuvant therapies in patients with anaplastic oligodendrogliomas. Characteristic chromosomal aberrations have been successfully determined for oligodendroglial tumors in recent years. In contrast to astrocytomas, however, no genes in the affected regions have been clearly linked to their pathogenesis. However, the molecular findings promise to be helpful for diagnostic and therapeutic decisions. This review compiles clinical, pathological, and molecular genetic findings on WHO grades II and III oligodendrogliomas and oligoastrocytomas.
少突胶质细胞瘤的发病率仅次于星形胶质细胞瘤。缺乏严格的诊断标准导致在这些肿瘤的分类和分级方面观察者间差异很大。以往的研究描述了少突胶质细胞瘤具有与神经细胞瘤重叠的特征,从而使诊断决策更加复杂。间变性少突胶质细胞瘤患者辅助治疗的益处凸显了对这一亚型胶质瘤制定标准化诊断标准的迫切需求。近年来已成功确定了少突胶质细胞瘤的特征性染色体畸变。然而,与星形细胞瘤不同,受影响区域的基因尚未明确与其发病机制相关联。不过,分子学研究结果有望有助于诊断和治疗决策。本综述汇编了世界卫生组织二级和三级少突胶质细胞瘤及少突星形细胞瘤的临床、病理和分子遗传学研究结果。